Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.9M | $22.2M | $24.3M | $116M | $25.1M | $48.7M | $68.7M | $34.3M |
| Revenue growth | — | 104.3% | 9.2% | 375.7% | -78.3% | 94.1% | 41.0% | -50.1% |
| Operating income | -$47.9M | -$87.2M | -$110M | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| Operating margin | -440.2% | -392.1% | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Net income | -$46.0M | -$92.9M | -$109M | -$30.6M | -$112M | -$61.3M | $7.17M | -$45.7M |
| Net margin | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
| EPS (diluted) | -$2.92 | -$2.21 | -$2.09 | -$0.52 | -$38.10 | -$15.96 | $1.04 | -$3.56 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.7M | -$71.0M | -$87.4M | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M |
| Capital expenditures | $14.3M | $24.7M | $5.03M | $5.05M | $3.32M | $1.96M | $250K | $85.0K |
| Free cash flow | -$66.0M | -$95.7M | -$92.4M | -$15.9M | -$49.1M | -$86.1M | -$58.7M | -$65.9M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $103M | $181M | $89.8M | $144M | $190M | $117M | $85.9M | $111M |
| Total assets | $139M | $235M | $150M | $211M | $238M | $160M | $136M | $154M |
| Total liabilities | $98.6M | $96.9M | $106M | $120M | $178M | $141M | $80.0M | $62.2M |
| Long-term debt | — | — | — | $2.48M | $22.2M | — | — | — |
| Shareholders' equity | $40.0M | $138M | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Retained earnings | -$85.2M | -$177M | -$286M | -$317M | -$428M | -$490M | -$482M | -$528M |
| Shares (wtd avg diluted) | 15.9M | 51.2M | 52.7M | 58.7M | 2.93M | 3.84M | 6.88M | 12.8M |
Every figure is extracted from PRECISION BIOSCIENCES INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.